Pieris loses Servier as partner for cancer immunotherapies

July 5, 2024


In a Securities & Exchange Commission (SEC) filing, Pieris said that Servier will exit the agreement between the two companies – first agreed in 2017 and focusing on the development of several Anticalin-based therapeutics for cancer – before the end of the year.

The prompt for Servier’s exit was a decision to stop dosing S095012 (formerly PRS-344), a 4-1BB/PD-L1 bispecific protein, in a phase 1 trial. Pieris said it intends to review the safety data from the S095012 study to understand the implications of the data, but does not intend to pursue any further development of the drug.

Read More on Pharmaphorum